Abzena enables the development of better treatments for patients, through its work with the top biopharmaceutical companies and academic groups worldwide.
Acacia Pharma develops and commercialises supportive care products for post-surgical and cancer patients. The company addresses these opportunities through repurposing.
Accera is a private Phase 3 development company pioneering novel therapeutics to address metabolic deficiencies in CNS disorders.
Adaptimmune, a leader in T-cell therapy, is a clinical-stage biopharmaceutical company, with a SPEAR T-cells pipeline in 10 solid tumors.
ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs.
The Advanced Centre for Biochemical Engineeering hosts the MBI® Modular Training Programme for the Bioindustries.